Compliance is never optional, but flexibility should be.

Two key themes from the Medicaid Drug Rebate Summit: defensible documentation and responsible AI. The Pricing Group explores what these priorities mean for Government Pricing teams navigating an evolving compliance landscape.

AI can support Government Pricing by improving efficiency and research, but it shouldn’t replace human judgment. GP calculations require regulatory expertise, accountability, and careful protection of sensitive data.

Fall brings key GP deadlines, including Q4 PHS/340B pricing on September 15 and August AMP on September 30. We also cover the MDRP Summit and timely topics such as Public Law season and proposed Medicare Part D claims reporting changes.

Accurate GP calculations are only part of audit readiness. Strong documentation, traceability, and internal ownership are critical to defending your methodology, reducing audit risk, and supporting those who certify your submissions.

August brings key Government Pricing deadlines, industry events, and regulatory developments. From NFAMP and 340B pricing to Medicare Part D and the MDRP Summit, here's what manufacturers should have on their radar.

Your Government Pricing partner may be meeting expectations—but are they delivering the full value your organization deserves? Discover why an independent GP audit can strengthen compliance, transparency, and confidence.

July is packed with critical GP deadlines, new CMS Bona Fide Service Fee reporting requirements, and continued proposed legislation aimed at congressional focus on the 340B Program to increase transparency and oversight. Read the full update.

Your GP reports may reconcile perfectly—but could you defend every number in an audit? Learn why understanding the methodologies, assumptions, and controls behind your GP calculations is just as important as delivering accurate results.

Use June's traditionally quieter stretch to get ahead of the updated ASP reporting requirements that will take effect with the Q2 submission due July 30.

Our team brings deep expertise in regulatory interpretation, methodology design, and audit readiness, helping you navigate one of the most complex areas of pharmaceutical finance with clarity and confidence.

On April 2, 2026, a proclamation was issued imposing tariffs on imports of pharmaceuticals, with staggered effective dates, July 31, 2026, for certain large companies and September 29, 2026, for all others.

CMS released instructions and forms associated with the new Average Sales Price (ASP) reporting and certification obligations, effective with the Q1 2026 submission.

While activity in the Government Pricing world seems to have slowed slightly, there are still several important upcoming deadlines and items to keep on your radar.

Well-drafted, current policies demonstrate good-faith compliance efforts and can be critical in defending against audits, government inquiries, and enforcement actions.

By now, your Medicaid, PHS/340B, and Medicare calculations for Q4/December 2025 should be wrapped up, which means it’s about time to get started on your next monthly calculations!

Happy New Year! A new year often brings new ideas, connections, and opportunities. As you may have seen from our recent announcement, Lisa Clayton has stepped into the role of Executive Director, and Katie Lapins has transitioned to Senior Advisor.

As we begin the new year, we are pleased to announce important leadership updates within The Pricing Group, effective today.

For many in GP, it’s “the most wonderful time of the year!" Here are a few upcoming GP-related activities and deadlines to note.

If you’re like us at The Pricing Group, October has proven to be as busy as we expected. Read more about upcoming GP deadlines!

October marks the start of an especially busy period in Government Pricing. Here are a few upcoming GP-related activities and deadlines to note.

As we shift into September, your Q2 Medicaid invoices should have started coming in. Learn more about other upcoming GP deadlines and activities of note.

July has been a busy month for The Pricing Group, and if you’re like us, you’ve just wrapped up most things for your Q2 reporting. Read more about upcoming GP deadlines!

We hope you had a happy and safe Fourth of July celebration! We have a few noteworthy topics, reminders, and deadlines to mention. Also, Crossroads 2025 is right around the corner!

As expected, the Department of Health and Human Services (HHS) submitted their PHS/340B Rebate Proposal to the Office of Management and Budget (OMB) for review.

Happy May! Did you know that May Day started out as a celebration of spring with the resurrection of nature after the long winter months? That feels appropriate after the winter many of us experienced! Here are some upcoming GP-related deadlines.

April is here, and spring has sprung (or is on its way!) for many of us. Here are just a few upcoming GP-related activities and deadlines to note.

The more things change, the more they stay the same. Even though it’s the beginning of a new year, there’s a new administration in the White House, and there’s still a lot going on in Government Pricing.

By now, your Q4 and December 2024 calculations should be about wrapped up! If you are in the Government Pricing (GP) space, that means it’s about time to get started on your next monthly calculations.

A new year often brings new ideas, connections, and opportunities. At The Pricing Group, we’re excited about 2025 and the ever-changing world of Government Pricing.

On September 20, 2024, CMS issued the Misclassification of Drugs, Program Administration and Program Integrity Updates Under the Medicaid Drug Rebate Program Final Rule (Final Rule) that is related to the Proposed Rule issued May 24, 2023.

Unsure if you’re ready for a Government Pricing audit? An assessment might be a better fit for your company. Read the differences below, and let us know if you have any additional questions. We’d be happy to point you in the right direction!

On April 19, 2024, the Health Resources and Services Administration (HRSA) issued a Final Rule with regards to the administrative dispute resolution process (ADR) between manufacturers and Covered Entities (CEs) who participate in the 340B Program.

It’s a busy time in Government Pricing! Late last week, we had the decision from the United States Court of Appeals for the Fourth Circuit regarding the Patient definition for purposes of the 340B Program.